BUGWORKS Research

What BUGWORKS Research does

Bugworks Research is a clinical-stage biopharmaceutical company, founded in 2014 and incubated at the Centre for Cellular and Molecular Platforms (C-CAMP) in Bangalore, India, with operating entities in India, a US parent (Bugworks Research, Inc., Delaware) and an Australian subsidiary (Bugworks Research Australia PTY. Ltd., Adelaide). Its stated mission is the discovery and development of novel pharmaceutical assets to address two therapeutic gaps: antimicrobial resistance (AMR) and recalcitrant cancers. The core scientific team is described as carrying 200+ years of combined drug discovery experience, with the co-founding leadership still in place (CEO Anand Anandkumar, COO Bala Subramanian, CSO Santanu Datta) and a Global Advisory Board including former Department of Biotechnology Secretary Dr. Renu Swarup.

The company's technology platform centers on the proprietary GYROX system, which generates Novel Bacterial Topoisomerase Inhibitors (NBTIs) that dually target bacterial DNA gyrase and Topoisomerase IV. The lead antibacterial candidate, BWC0977, is described as an IV plus oral step-down agent for serious bacterial infections and one of the first novel broad-spectrum antibiotics in decades to enter clinical trials; a successor program GYROX NXTGEN targets both critical priority and biothreat pathogens. The immuno-oncology pipeline comprises multiple small molecule programs targeting the adenosine axis (BWC2094), CDK7 (BWC5044/BWC5077), ATM/DNA-PK dual (BWC5036/BWC5089), HPK1 (BWC4496), spliceosome modulation/DNA damage (BWC5167), PTPN1/2 dual, CDK2, human Topo I (potential ADC payload) and ENT1, with claimed activity across CRC, NSCLC, TNBC, pancreas, prostate, RCC and HNSCC tumors. Lead programs have produced peer-reviewed publications (e.g., Nature Communications, Journal of Antimicrobial Chemotherapy) and clinical/regulatory validations through CARB-X (2017 grant), DTRA (2021 biothreat funding), and a flagship co-development partnership with GARDP (2023, expanded July 2025 for oral formulation).

Commercially, Bugworks operates an asset-development model targeting eventual licensing to larger pharmaceutical companies, co-development with global health organizations such as GARDP, and government/defense procurement for biothreat indications. The company is privately held and venture-backed, having raised a disclosed Series A of $9M (2018, UTEC and Global Brain), a $7.5M round in 2020, an $18M Series B1 in February 2022 led by Lightrock India, an SEC-registered exempt offering of approximately $15.78M in March 2024, and additional non-dilutive grant capital from CARB-X, DTRA and India's Department of Biotechnology. Future customers are characterized as healthcare systems and hospitals treating multidrug-resistant infections, government health agencies for biothreat coverage, and licensing partners in pharma — though the company has not yet disclosed commercial revenue, pricing for any of its drug candidates, or a launch date.

Name

BUGWORKS Research

Legal name

Bugworks™ Research India Pvt. Ltd.

Website

https://bugworksresearch.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Bugworks Research is a clinical-stage biopharmaceutical company developing novel broad-spectrum antibacterial agents and immuno-oncology therapeutics. Founded in 2014 at C-CAMP Bangalore, it targets antimicrobial resistance and recalcitrant cancers via proprietary dual-targeting small molecule platforms.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Antimicrobial drug discovery
• Novel antibacterial agents
• Immuno-oncology therapeutics
• Small molecule therapeutics
• AMR drug development

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Development and Licensing: Bugworks develops novel therapeutic assets through clinical stages and plans to commercialize through licensing agreements with larger pharmaceutical companies, co-development partnerships, and eventual product sales. The company has received funding from CARB-X, GARDP, DTRA, and government grants to support development.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

BUGWORKS Research is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapeutics in two therapeutic areas: broad-spectrum antibacterial agents to combat antimicrobial resistance (AMR) and next-generation immuno-oncology drugs. Its lead clinical asset, BWC0977, is an IV and oral step-down antibiotic targeting critical priority pathogens, with the proprietary GYROX platform producing novel bacterial topoisomerase inhibitors (NBTIs) that dually target DNA gyrase and Topoisomerase IV.

Product overview

Bugworks Research is a clinical-stage biopharmaceutical company developing a portfolio of novel small molecule therapeutics across two main therapeutic areas: anti-bacterial agents and immuno-oncology. The AMR pipeline centers on BWC0977 and GYROX NXTGEN as lead candidates targeting critical care infections with IV and oral formulations. The oncology portfolio includes multiple targeted therapy candidates including BWC2094 (adenosine axis effector), BWC5044/BWC5077 (CDK7 inhibitors), BWC5036/BWC5089 (ATM/DNA-PK dual inhibitors), BWC4496 (HPK1 inhibitor), BWC5167 (spliceosome modulators), PTPN1/2 dual inhibitors, CDK2 inhibitor, Human Topo I inhibitor, and ENT1 inhibitor. The company's GYROX platform represents its proprietary dual-targeting broad-spectrum antibacterial technology.

Differentiator

Problem solved

Functional benefit

Products and services

• BWC0977 IV + oral step-down small molecule antibacterial agent in clinical development for treating critical care infections caused by multidrug-resistant bacteria, including WHO critical priority pathogens and biothreat organisms.
• GYROX NXTGEN IV + oral step-down small molecule antibacterial agent for treating critical care and community infections with broad-spectrum coverage against critical priority pathogens, high priority pathogens, and biothreat pathogens.
• BWC2094 Triple effector of the adenosine axis for immuno-oncology applications, targeting the adenosine pathway implicated in multiple solid tumors including colorectal cancer (CRC), NSCLC, TNBC, pancreas, prostate, RCC, and HNSCC.
• BWC5044 / BWC5077 (CDK7 Inhibitors) Small molecule CDK7 inhibitors being developed as oncology therapeutics for treating recalcitrant tumors.
• BWC5036 / BWC5089 (ATM/DNA-PK Dual Inhibitors) Dual inhibitors of ATM and DNA-PK developed as small molecule oncology therapeutics for treating recalcitrant tumors.
• BWC4496 (HPK1 Inhibitor) HPK1 inhibitor small molecule for enhancing anti-tumor immunity as part of the immuno-oncology portfolio.
• BWC5167 (Spliceosome Modulator / DNA Damage Therapeutic) Spliceosome modulators and DNA damage response small molecule therapeutics for treating recalcitrant tumors, with potential application as an antibody-drug conjugate (ADC) payload.
• PTPN1/2 Dual Inhibitor

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered flagship, major, core and minor.

• GARDP (Global Antibiotic Research and Development Partnership)flagshipStrategic or Co-development Partner · 11 June 2024Strategic partnership to co-develop BWC0977 with broad-spectrum antibiotic activity against multidrug-resistant bacteria. Expanded in July 2025 to include oral formulation development for serious bacterial infections.
• Cytecare Cancer HospitalsmajorStrategic or Co-development Partner · 18 September 2022Collaboration to accelerate development of cutting-edge immuno-oncology therapies combining Bugworks' small molecule therapeutics with Cytecare's cancer treatment expertise.
• C-CAMP (Centre for Cellular and Molecular Platforms)coreStrategic or Co-development PartnerBugworks was incubated in C-CAMP, Bangalore in 2014. C-CAMP is Karnataka's leading biotech innovation hub that supports startups through funding, clinical trials, and novel solutions.
• NIH (National Institutes of Health)majorStrategic or Co-development PartnerUS government health research agency engaged in partnerships for antibiotic development and AMR research.
• Dr. Renu SwarupminorOthersFormer secretary of Department of Biotechnology, Government of India joined Bugworks' Global Advisory Board in February 2023 to provide strategic guidance.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Wockhardt: Indian multinational pharmaceutical company with significant antibiotic pipeline targeting AMR. Operates from similar geography to Bugworks; provides geographic and therapeutic adjacency comparison as a larger Indian AMR player.
• Paratek Pharmaceuticals: Developed and commercialized omadacycline (Nuzyra) for community-acquired bacterial pneumonia and skin infections. Larger established antibiotic developer; acquired by Gurnet Point. Comparable antibacterial focus with broader commercial footprint.
• Achaogen: Formerly developed plazomicin (Zemdri) for complicated UTI; filed for bankruptcy in 2019 post-approval. Closely comparable historical peer whose trajectory highlights both the achievement of FDA approval for novel antibiotics and the commercial risks Bugworks could face.

Direct peers

• Entasis Therapeutics: Develops targeted antibacterial therapies including sulbactam-durlobactam for A. baumannii infections. Acquired by Innoviva in 2022. Closely comparable lead-asset positioning in critical-priority Gram-negative pathogens.
• Nabriva Therapeutics: Developed lefamulin (Xenleta) for community-acquired bacterial pneumonia. Comparable small-molecule antibiotic developer with similar clinical-stage profile and AMR focus.
• Iterum Therapeutics: Clinical-stage anti-infective company developing oral and IV antibiotics against multidrug-resistant pathogens including ESBL-producing Enterobacterales. Directly comparable to Bugworks in target indications (cUTI, uUTI, HABP/VABP) and Gram-negative focus.
• Melinta Therapeutics: Developed and commercialized antibiotics for serious bacterial infections (Baxdela, Vabomere, Orbactiv, Minocin). Comparable therapeutic focus on drug-resistant infections; restructured via acquisition in 2020 — illustrates AMR commercial risk.
• Cidara Therapeutics: Clinical-stage biopharmaceutical company developing novel anti-infectives including Cloudbreak antimicrobial conjugates. Comparable small-molecule antimicrobial development platform with similar clinical-stage profile.
• VenatoRx Pharmaceuticals: Private clinical-stage antibiotic developer with Phase 3 programs targeting multidrug-resistant Gram-negative infections, including partnerships with GARDP. Directly comparable mechanism class and development stage to BWC0977.
• Tetraphase Biosciences: Developed eravacycline (Xerava) for complicated intra-abdominal infections. Closely comparable clinical-stage antibiotic developer targeting MDR Gram-negative infections; illustrates commercialization challenges in AMR.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/anand_bugworks
• LinkedInlinkedin.com/company/bugworks

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BUGWORKS Research